posted on 2017-07-28, 00:00authored byLizanne
G. Nilewski, Melissa Singh, David S. Baskin, James M. Tour, Martyn A. Sharpe
Selective
targeting of drug loaded nanovectors to specific epitopes
highly expressed on the surface of cancer cells is a goal for nanotechnologists.
We have modified our previously described PEGylated-hydrophilic carbon
clusters (PEG-HCCs) so that the epidermal growth factor receptor (EGFR)
binding peptide, GE11, is attached using click chemistry at the end
of each PEG. The resulting nanosyringe, PepEGFR-PEG-HCC,
can be loaded with a wide range of hydrophobic drugs and dyes. We
show that, both in vitro and in vivo, this payload can be delivered
to cancer cells expressing EGFR. We can observe the activation of
EGFR and track the normal physiological internalization and recycling/signaling
pathways of this tyrosine kinase following binding of PepEGFR-PEG-HCC. We also demonstrate the competitive binding of the nanosyringe
to EGFR with its normal activator, EGF, as well as observing the colocalization
of the nanosyringe with clathrin, the coated pit integral protein.
The internalization of the drug/dye loaded nanosyringe can be inhibited
by using anti-EGFR antibodies, the drug erlotinib, or Pitstop-1, the
clathrin coated pit formation specific inhibitor. To further demonstrate
the specificity of the drug loaded nanovectors, we demonstrated that,
in both flank and intracranial xenograft mouse models, dye delivery
is highly specific to tumors and no other tissues. Finally, using
nanosyringes loaded with esterase sensitive fluorescein diacetate,
we demonstrated that the drug payloads can be in vivo delivered to
the cytosol of cancer cells within the mouse brain.